… Women entered the BCPT trial without knowledge of their inherited BRCA1 or BRCA2…
BRCA1 and BRCA2 sequenced. This report presents the genetic analysis of BRCA1 and BRCA2 …

… of tamoxifen for BRCA1 and BRCA2 mutation carriers come from a subgroup analysis of
the prospectively randomized NSABP-P1 breast cancer prevention trial. NSABP-P1 followed …

… There were 3722 women with a BRCA1 or BRCA2 mutation included in the current
analysis. The baseline characteristics are summarized in Table 1; 1552 women had a bilateral …

… -P1 (NSABP-P1) trial which included 19 documented BRCA mutation carriers [20]. The
current recommendation for breast cancer prevention with tamoxifen for women at high-risk is …

… of this study was to analyze the impact of RRSO on carriers of BRCA1 and BRCA2 mutations
independently, four participants with mutations in both BRCA1 and BRCA2 were excluded. …

… Given all of the data, the most parsimonious explanation of these conflicting data are that
the NSABP-P1 study was underpowered to detect a protective effect of tamoxifen in BRCA1/2 …

… the BRCA1/2 mutation status by genetic screening of the entire BRCA1 and BRCA2 genetic
… women in either our trial or in the NSABP-P1 trial [17] with proven pathogenic BRCA1 or …

… Using genotyping data from women receiving tamoxifen and raloxifene in the NSABP P-1
and P-2 studies, we have shown that a PRS of the 75 loci is a risk factor for breast cancer in …

… breast cancers in 76 BRCA1/2 mutation carriers after 2.9 years of … breast cancer risk reduction
in BRCA1/2 mutation carriers, but … of breast cancer in 483 BRCA1/2 mutation carriers (105 …

… We review the management for unaffected BRCA1/2 mutation carriers and the local … and
decreased mortality in BRCA1/2 mutation carriers. In women with BRCA1/2 mutations who have …